Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Filothei – page 9

270 clinical trials in Filothei, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Filothei at a glance
270
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

270 trials in Filothei

Open in trial search

Study Comparing Iberdomide and Lenalidomide for Maintenance Therapy After Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Celgene Corp.

Phase 3 Study of Ivonescimab Versus Durvalumab as Consolidation Therapy in Patients with Unresectable Stage III Non‑Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Summit Therapeutics Inc.

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Type 2 diabetes mellitus

Not yet recruiting

Study of zenagamtide versus insulin glargine in adults with type 2 diabetes and high cardiovascular risk uncontrolled on oral medications

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Insulin Glargine
  • Sponsor:Novo Nordisk A/S

Ocular myasthenia

Not yet recruiting

Phase 3 Open‑Label Extension Study of Long‑Term Safety and Efficacy of Rozanolixizumab in Adults with Ocular Myasthenia Gravis

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Rozanolixizumab
  • Sponsor:UCB Biopharma

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Non-small cell lung cancer

Not yet recruiting

Study of N-803, tislelizumab and docetaxel combination versus docetaxel alone for patients with advanced or metastatic non-small cell lung cancer resistant to immune checkpoint inhibitors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Immunitybio Inc.

Malignant peritoneal neoplasm+1

Not yet recruiting

Maintenance therapy with raludotatug deruxtecan alone or with bevacizumab versus standard care in patients with newly diagnosed advanced ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal adenocarcinoma

Not yet recruiting

Phase 2 Study of ro7589831 with Pembrolizumab vs Pembrolizumab Alone in Adults with Advanced Colorectal Cancer (MSI‑High or dMMR)

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Vividion Therapeutics Inc.

Anaemia+1

Not yet recruiting

Study of Elritercept (TAK‑226) with Ruxolitinib vs Placebo in Patients with Myelofibrosis and Anemia on Ruxolitinib Therapy

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

VEXAS syndrome

Not yet recruiting

A Randomized, Double‑Blind, Placebo‑Controlled Study of Momelotinib Dihydrochloride Monohydrate in Patients with VEXAS Syndrome

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Filothei

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on platinum-sensitive ovarian cancer and advanced breast cancer treatments, evaluating new combination therapies and maintenance approaches.

  • Ovarian, Fallopian Tube, and Peritoneal Cancers
  • HER2-Positive Breast Cancer
  • Estrogen Receptor-Positive Breast Cancer

Multiple studies examining targeted therapies and novel drug combinations to improve patient outcomes.

02 Neurological Disorders

Research initiatives targeting rare neurological conditions, including studies on Lennox-Gastaut syndrome and innovative treatments for seizure management.

  • Seizure Disorders
  • Neuromuscular Conditions
  • Pediatric Neurological Disorders

Focused on developing new therapeutic approaches for complex neurological conditions.

03 Rare Diseases

Specialized research programs investigating treatments for Duchenne muscular dystrophy, exploring novel therapeutic approaches and dosing strategies.

  • Genetic Disorders
  • Progressive Muscle Conditions
  • Pediatric Rare Diseases

Evaluating innovative treatments to address unmet medical needs in rare disease populations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.